Osborne G E N, Pagliuca A, Ho A, du Vivier A W P
Departments of Dermatology and Haematology, King's College Hospital, Denmark Hill, London SE5 9RS, UK.
Br J Dermatol. 2006 Sep;155(3):617-20. doi: 10.1111/j.1365-2133.2006.07355.x.
We describe a patient with erythrodermic adult T-cell leukaemia/lymphoma resistant to multiple systemic therapies who, on the commencement of daclizumab, a humanized anti-interleukin-2 receptor antibody, developed a rapid and sustained complete response with resolution of previously debilitating erythroderma, suggesting significant activity of this agent in this disease process.
我们描述了一名患有红皮病型成人T细胞白血病/淋巴瘤的患者，该患者对多种全身治疗均耐药，在开始使用人源化抗白细胞介素-2受体抗体达利珠单抗后，迅速且持续地出现了完全缓解，之前使人衰弱的红皮病也得到了缓解，这表明该药物在这一疾病过程中具有显著活性。
